X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUVEN LIFESCIENCES - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUVEN LIFESCIENCES GLENMARK PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 13.1 19.1 68.6% View Chart
P/BV x 2.3 3.7 62.8% View Chart
Dividend Yield % 0.4 0.6 73.2%  

Financials

 GLENMARK PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
SUVEN LIFESCIENCES
Mar-18
GLENMARK PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs930251 370.8%   
Low Rs517155 333.8%   
Sales per share (Unadj.) Rs322.649.1 656.7%  
Earnings per share (Unadj.) Rs28.59.7 293.2%  
Cash flow per share (Unadj.) Rs39.211.4 344.0%  
Dividends per share (Unadj.) Rs2.001.50 133.3%  
Dividend yield (eoy) %0.30.7 37.4%  
Book value per share (Unadj.) Rs183.060.3 303.5%  
Shares outstanding (eoy) m282.17127.28 221.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.1 54.3%   
Avg P/E ratio x25.420.9 121.7%  
P/CF ratio (eoy) x18.517.8 103.7%  
Price / Book Value ratio x4.03.4 117.5%  
Dividend payout %7.015.4 45.5%   
Avg Mkt Cap Rs m204,20625,825 790.7%   
No. of employees `00013.71.1 1,279.5%   
Total wages/salary Rs m18,718613 3,055.1%   
Avg. sales/employee Rs Th6,636.85,832.6 113.8%   
Avg. wages/employee Rs Th1,364.7571.5 238.8%   
Avg. net profit/employee Rs Th586.11,153.8 50.8%   
INCOME DATA
Net Sales Rs m91,0316,253 1,455.9%  
Other income Rs m914233 392.8%   
Total revenues Rs m91,9456,485 1,417.7%   
Gross profit Rs m16,1541,982 815.1%  
Depreciation Rs m3,019213 1,416.6%   
Interest Rs m2,85646 6,167.8%   
Profit before tax Rs m11,1931,955 572.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155718 439.2%   
Profit after tax Rs m8,0391,237 649.9%  
Gross profit margin %17.731.7 56.0%  
Effective tax rate %28.236.7 76.7%   
Net profit margin %8.819.8 44.6%  
BALANCE SHEET DATA
Current assets Rs m69,8875,622 1,243.0%   
Current liabilities Rs m32,8791,168 2,815.9%   
Net working cap to sales %40.771.2 57.1%  
Current ratio x2.14.8 44.1%  
Inventory Days Days8181 100.0%  
Debtors Days Days9336 260.3%  
Net fixed assets Rs m28,8923,325 869.0%   
Share capital Rs m282127 221.7%   
"Free" reserves Rs m51,3537,547 680.5%   
Net worth Rs m51,6357,674 672.8%   
Long term debt Rs m41,41814 297,969.8%   
Total assets Rs m125,9549,135 1,378.8%  
Interest coverage x4.943.2 11.4%   
Debt to equity ratio x0.80 44,285.1%  
Sales to assets ratio x0.70.7 105.6%   
Return on assets %8.614.0 61.6%  
Return on equity %15.616.1 96.6%  
Return on capital %15.126.0 58.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,3175,066 716.9%   
Fx outflow Rs m9,7202,001 485.7%   
Net fx Rs m26,5983,065 867.8%   
CASH FLOW
From Operations Rs m16,481699 2,356.4%  
From Investments Rs m-10,133-6 166,121.3%  
From Financial Activity Rs m-4,685-577 812.0%  
Net Cashflow Rs m1,770116 1,521.9%  

Share Holding

Indian Promoters % 48.3 63.4 76.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.0 -  
FIIs % 34.4 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 36.5 28.8%  
Shareholders   56,727 37,287 152.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 17, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS